The Clinical Impact and Incidence of Periocular Pigmentation Associated with either Latanoprost or Bimatoprost Therapy

REFERENCES

• Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: A comparison with timolol. Ophthalmology 1995; 102: 1743–1752
   PubMed Web of Science ®Google Scholar
• Camras C B, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month, masked, multicenter trial in the United States. Ophthalmology 1996; 103: 138–147
   PubMed Web of Science ®Google Scholar
• Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996; 103: 126–137
   PubMed Web of Science ®Google Scholar
• Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000; 41: 2566–2573
   PubMed Web of Science ®Google Scholar
• Stewart W C, Holmes K T, Johnson M A. Washout periods for brimonidine 0.2% and latanoprost 0.005%. Am J Ophthalmol. 2001; 131: 798–799
   PubMed Web of Science ®Google Scholar
• Susanna R, Jr, Giampani J, Jr, Borges A S, Vessani R M, Jordao M L. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology. 2001; 108: 259–263
   PubMed Web of Science ®Google Scholar
• Parrish R K, Palmberg P, Sheu W-P, for the XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator, multicenter study. Am J Ophthalmol. 2003; 135: 688–703
   PubMed Web of Science ®Google Scholar
• Dubiner H, Cooke D, Dirks M, Stewart W C, Van Denburgh A M, Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: A 30-day comparison with latanoprost. Surv Ophthalmol. 2002; 45: S353–S360
   Google Scholar
• Noecker R S, Dirks M S, Choplin N T, et al. A six-month randomized clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003; 135: 55–63
   PubMed Web of Science ®Google Scholar
• Gandolfi S, Simmons S T, Sturm R, Chen K, Van Denburgh A M, Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001; 18: 110–121
   PubMed Web of Science ®Google Scholar
• Konstas A GP, Katsimbris J M, Lallos N, Boukaras G P, Jenkins J N, Stewart W C. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 2005; 112: 262–266
   PubMed Web of Science ®Google Scholar
• Stewart W C. Prostaglandin analogues: Their usage and benefits in glaucoma treatment. Ophthalmic Practice, 1996; 14: 48–55
   Google Scholar
• Wand M, Ritch R, Isbey E K, Jr, Zimmerman T J. Latanoprost and periocular skin color changes. Arch Ophthalmol. 2001; 119: 614–615
   PubMed Web of Science ®Google Scholar
• Herndon L W, Williams R D, Wand M, Asrani S. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans. Am J Ophthalmol. 2003; 135: 713–715
   PubMed Web of Science ®Google Scholar
• Sodhi P K, Verma L, Ratan S K. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans. Am J Ophthalmol. 2004; 137: 783
   Web of Science ®Google Scholar
• Book S A. Essentials of Statistics. McGraw-Hill, New York 1978
   Google Scholar
• Teus M A, Arranz-Marquez E, Lucea-Suescun P. Incidence of iris colour change in latanoprost treated eyes. Br J Ophthalmol. 2002; 86: 1085–1088
   PubMed Web of Science ®Google Scholar
• Chiba T, Kashiwagi K, Ishijima K, Furuichi M, Kogure S, Abe K, Chiba N, Tsukahara S. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost. Jpn J Ophthalmol. 2004; 48: 141–147
   PubMed Web of Science ®Google Scholar
• Chou S Y, Chou C K, Kuang T M, Hsu W M. Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes. Eye. 2005; 19: 7684–7687
   Google Scholar
• Stjernschantz J W, Albert D M, Hu D N, Drago F, Wistrand P J. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol 2002; 47: S162–S175, Suppl 1
   PubMed Web of Science ®Google Scholar
• Albert D M, Gangnon R E, Zimbric M L, Damico C M, Fisher M R, Gleiser J, Grossniklaus H E, Green W R. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients. Arch Ophthalmol. 2004; 122: 1680–1685
   PubMedGoogle Scholar
• Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol. 2004; 122: 957–965
   PubMed Web of Science ®Google Scholar
• Johnstone M A. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997; 124: 544–547
   PubMed Web of Science ®Google Scholar
• Netland P A, Landry T, Sullivan E K, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini M V, Robertson S M, Davis A A, Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132: 472–484
   PubMed Web of Science ®Google Scholar
• Sherwood M, Brandt J. Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001; 45: S361–S368, (Suppl 4)
   Web of Science ®Google Scholar